Study on SPECT-CT Guided Treatment for Patients with One-Sided Oropharyngeal Cancer

Sponsor: Canadian Cancer Trials Group

Sponsor score: 0
Inactive

ClinicalTrials ID:NCT05451004

Provider View

This clinical trial is exploring whether using a special imaging technique called SPECT-CT to guide radiotherapy can be as effective as the usual treatment for preventing cancer spread or return in patients with one-sided oropharyngeal cancer.

Patient Parameters

Program Overview

The purpose of this study is to determine if using SPECT-CT imaging to guide radiotherapy to the neck is as effective as the standard approach, which involves treating both sides of the neck, in controlling cancer and reducing side effects. The standard treatment for patients not in a study includes radiotherapy to the tumor and both sides of the neck to lower the risk of cancer spreading or coming back.

Description

This study aims to find out if using a special imaging technique called SPECT-CT to guide radiotherapy can be as effective as the usual treatment for controlling cancer and improving quality of life. Typically, patients receive radiotherapy to both sides of the neck to reduce the risk of cancer spreading or returning. This study will compare the new approach to the standard treatment to see if it offers similar benefits with fewer side effects.

Eligibility Criteria

Inclusion Criteria

  • Diagnosed with one-sided oropharyngeal cancer (tonsil, tongue base, soft palate, or pharyngeal wall) that does not cross the midline.
  • Can be HPV positive or negative.
  • Cancer stage T1-3 M0, with possible lymph node involvement on the same side, but no larger than 6 cm.
  • Recent imaging tests, including CT or MRI of the neck, PET-CT scan, and chest CT scan.
  • Planned radiotherapy to both sides of the neck, with or without chemotherapy.
  • ECOG performance status of 0, 1, or 2, indicating good overall health.
  • Willing to complete quality of life questionnaires.
  • Able to provide informed consent and attend follow-up appointments.
  • Radiotherapy to start within 28 days of randomization.
  • Willing to use effective contraception if of childbearing potential.
  • Previous or concurrent cancers that do not interfere with the study are allowed.
  • Consent to provide a tumor tissue sample for research purposes.

Exclusion Criteria

  • Small cancers isolated to the tonsil area without lymph node involvement or with a single small lymph node.
  • Previous complete removal of tonsils with no remaining cancer.
  • History of head and neck cancer or multiple head and neck cancers.
  • Previous chemotherapy or radiation therapy to the head and neck.
  • Allergy to the radiotracer used in imaging.
  • Severe health conditions, such as recent lung or heart problems, that could interfere with treatment.

Get This Program In Your Inbox

Receive detailed information about this treatment opportunity to review with your healthcare provider.